Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of SAR445877 in advanced solid tumors
2023-507141-28-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of SAR445877 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 7 more (4 arms), sponsored by Sanofi. Primary endpoints: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2 (Dose escalation Part 1A and Japan Cohort F), Percentage of participants experiencing treatment-emergent adverse events (TEAEs) (Dose escalation and Japan Cohort F) and 2 more. Planned start Oct 2024; status: authorised.
02
Drugs
SAR445877
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-507141-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507141-28-00.